Embecta CORP 8-K filings

Embecta Corp. reported third quarter fiscal year 2026 financial results, showing a year-over-year revenue decrease of 8.1% to $271.7 million, though sequential revenue improved by $50 million.

Embecta Corp. has filed an amendment to its Form 8-K to include the audited financial statements of Owen Mumford Holdings Limited and pro forma financial information following its acquisition.

Embecta Corp. has finalized its acquisition of UK-based medical device innovator Owen Mumford Holdings Limited for an upfront cash payment and potential milestone-based payments.

Embecta Corp. reported a significant decline in second-quarter fiscal 2026 revenue and lowered its full-year financial guidance, citing challenges in its U.S. business and the impending acquisition of Owen Mumford.

Embecta Corp. announced the results of its 2026 Annual Meeting of Stockholders, with all director nominees elected and key proposals approved.

Embecta Corp. reported largely expected first-quarter fiscal 2026 financial results, with revenues of $261.2 million and a focus on strategic transformation and debt reduction.

Embecta Corp. reported mixed fiscal year 2025 results with revenue declines but improved profitability, exceeding adjusted operating and EBITDA margin targets, while providing initial fiscal year 2026 guidance.

Embecta Corp. announced changes to its Board of Directors, including two resignations and the planned appointment of a new Chairman and Lead Independent Director.

Embecta Corp. announced robust third-quarter fiscal 2025 financial results, driven by solid commercial execution and strategic operational advancements, leading to a tightened and raised full-year outlook.

Embecta Corp. reaffirms its commitment to long-term growth by presenting its long-range financial plan and strategic priorities at its 2025 Analyst and Investor Day.

Embecta Corp. reports Q2 fiscal year 2025 financial results, showing a revenue decrease but improved profitability metrics and reaffirming adjusted EPS guidance despite lowered revenue expectations.

Embecta Corp. held its Annual Meeting of Stockholders on February 12, 2025, and all proposals were approved, including the election of directors, ratification of the auditor, and advisory vote on executive compensation.

Embecta Corp. reports a 5.6% decrease in revenue for Q1 2025 but raises expectations for key financial metrics and announces an upcoming Investor and Analyst Day.

Embecta Corp. has appointed Anthony Roth as Vice President, Chief Accounting Officer and Corporate Controller, effective December 2, 2024, replacing Jake Elguicze in that role.

Embecta Corp. will discontinue its insulin patch pump program and initiate a restructuring plan to streamline operations and reduce costs, while reporting mixed financial results for fiscal year 2024.

Embecta Corp. has announced the resignation of its Chief Accounting Officer, Brian Capone, effective August 12, 2024, and has appointed the current CFO, Jake Elguicze, as interim Principal Accounting Officer.

Embecta Corp. reported a slight revenue decrease for the third quarter of fiscal year 2024, but increased its full-year financial outlook.

Embecta Corp. reported strong second-quarter results, exceeding expectations and leading to an increased fiscal year 2024 outlook.

Embecta Corp. has secured extensions to its Transition Services Agreement and Logistics Services Agreement with Becton, Dickinson and Company, ensuring continued support for its business operations in specific international markets until November 1, 2024.

Embecta Corp. held its annual meeting on February 7, 2024, where stockholders voted on the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the equity compensation plan.

Embecta Corp. reported strong first-quarter fiscal 2024 results, exceeding expectations and raising its full-year financial guidance.